Haemostatix Ltd

Haemostatix is a biopharmaceutical company developing first-in-class therapies for the treatment of bleeding or ‘haemostasis’. The company has pioneered a new approach to haemostasis based on targeting fibrinogen, a key protein in the blood clotting process. This innovative technology platform is being used to develop a pipeline of systemic and topical products to prevent or control different forms of bleeding.

Haemostatix's lead product is HaemoPlax™, a platelet substitute in development for the prevention of bleeding in leukaemic patients with platelet deficiency or ‘thrombocytopenia’. 

The Company's pipeline contains two further products. HXTC 901 is designed to control more active bleeds in thrombocytopenic patients, and in surgery or trauma. HXTC901 is a 'pro-drug' activated by the enzyme thrombin at a wound site. HXSA 902 is a topical haemostat / wound sealant that can be applied during surgery and is designed to control bleeding and seal incisions or wounds.